Krsnaa Diagnostics Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY2027) through a regulatory filing submitted to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

  • Revenue from operations grew 22% year-over-year to ₹2,355 million (compared to ₹1,930 million in the corresponding quarter of the previous year)
  • EBITDA stood at ₹588 million with an EBITDA margin of 25% (compared to ₹524 million and 27% margin in the previous year)
  • Profit After Tax (PAT) was ₹166 million with a PAT margin of 7% (compared to ₹205 million and 11% margin in the previous year)
  • Like-for-like projects (excluding new projects) grew approximately 12% year-over-year

Operational Highlights

Rajasthan Project Commissioning:

  • The Rajasthan pathology network transitioned from implementation to operations during the quarter
  • By quarter-end, 31 mother labs, 62 hub labs, and 1,228 collection centers were operational
  • The Rajasthan operations contributed ₹257 million of revenue in Q1 FY2027
  • Margin moderation was attributed to the upfront fixed cost base of Rajasthan laboratories, equipment, manpower, and logistics being carried ahead of full utilization

Retail Business:

  • Retail revenue grew approximately 64% year-over-year and 22% sequentially to ₹193 million
  • Retail network expanded to more than 4,250 touchpoints across five states

Other Developments:

  • 8 of 17 planned MRI centers in Maharashtra were inaugurated and made operational during the quarter
  • 12 new NABH accreditations were added
  • Apulki-Pune hospital commenced operations
  • The company secured a new CT project award in Himachal Pradesh for 34 CT scanners

Corporate Action

  • The Board approved the issue of share warrants to the Promoter and Promoter Group
  • The issuance is subject to applicable approvals and regulatory requirements

Management Commentary

Mr. Yash Mutha, Managing Director: "Q1 FY2027 reflects the growing strength of the platform we have built. Our existing business continues to grow, while Rajasthan and other new projects are adding a second layer of growth. With retail scaling rapidly and our newly commissioned infrastructure moving towards higher utilization, we remain focused on converting the platform we have built into sustainable, long-term value for our shareholders."

Mr. Mitesh Dave, Group Chief Executive Officer: "Q1 was a quarter of execution converting infrastructure into live, revenue-generating capacity. Rajasthan is now operational, our retail network has crossed 4000+ touchpoints and our radiology footprint continues to expand. As utilization builds across these investments, we expect the operating leverage inherent in our model to become increasingly visible."